phase readout
saveNCT06896916: Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
community read0 votes
Sponsor: AbbVie. Phase: PHASE1. Conditions: Multiple Myeloma
view source ↗Data sources
last refreshed 4h ago
Found something off?
same company · ±60 days · 6
- earningsAbbVie Inc. earningsOct 30, 2026
- earningsAbbVie Inc. earningsOct 29, 2026
- earningsAbbVie Inc. earningsJul 31, 2026
- earningsAbbVie Inc. earningsJul 30, 2026
- phase 1 2 completionblinatumomab: AbbVie Inc — blinatumomab (Phase I/II Trial Completion)Apr 30, 2026
- phase 1 2 completionvenetoclax: AbbVie Inc — venetoclax (Phase I/II Trial Completion)Apr 30, 2026
related news · 8
- biospaceFDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
- fiercebiotechFDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
- biopharma diveAt ASH, drugmakers to showcase early data for three-pronged cancer therapies
- fiercebiotechAbbVie abandons phase 2 solid tumor drug over ‘limited benefit’
- biospaceAbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
- fiercebiotechAbbVie scratches out phase 3 hidradenitis suppurativa win but falls short of expectations
- biospaceAs AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
- endpointsAbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial
🐶 often sniffed alongside
top 8- tagApproval168 co-mentions · 84 sources
- drugHUMIRA122 co-mentions · 61 sources
- drugadalimumab122 co-mentions · 61 sources
- drugABRILADA61 co-mentions · 61 sources
- drugYUSIMRY61 co-mentions · 61 sources
- drugAMJEVITA61 co-mentions · 61 sources
- drugSKYRIZI46 co-mentions · 23 sources
- drugrisankizumab46 co-mentions · 23 sources
comments(0)
5-min edit window · permanent after that